Voyager Therapeutics (VYGR) Stock Price, News & Analysis

Company Overview

Voyager Therapeutics, Inc. is a biotechnology company focused on developing gene therapies for neurological diseases. The company uses its proprietary TRACER capsid discovery platform to identify adeno-associated virus (AAV) capsids designed to improve the delivery of genetic medicines to the brain and central nervous system.

Voyager’s research and development programs have addressed conditions including Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis and Friedreich’s ataxia. Its pipeline has included therapies intended to replace or modify genes, reduce the production of disease-associated proteins, or deliver therapeutic antibodies and other biological payloads to the central nervous system.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Voyager has pursued collaborations and licensing arrangements with larger pharmaceutical companies to advance selected gene-therapy programs and apply its capsid technology across additional neurological targets. The company is led by Alfred Sandrock, M.D., Ph.D., who became chief executive officer in 2023 after holding senior research and development positions in the biotechnology industry.

Key Stats

• Today's Range: $2.42 to $2.73
• 50-Day Range: $2.45 to $3.54
• 52-Week Range: $2.42 to $5.55
• Volume: 1.17 million shs
• Average Volume: 549,856 shs
• Market Capitalization: $150.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.50
• Consensus Rating: Moderate Buy

Voyager Therapeutics Stock Analysis - MarketRank™

Voyager Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 520th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Voyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Voyager Therapeutics has a consensus price target of $16.50, representing about 573.5% upside from its current price of $2.45.

Amount of Analyst Coverage

Voyager Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Voyager Therapeutics are expected to grow in the coming year, from ($1.63) to ($1.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Voyager Therapeutics is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Voyager Therapeutics is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Voyager Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.80% of the float of Voyager Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Voyager Therapeutics has a short interest ratio ("days to cover") of 8.61.

Change versus previous month

Short interest in Voyager Therapeutics has recently decreased by 3.44%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Voyager Therapeutics does not currently pay a dividend.

Dividend Growth

Voyager Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for VYGR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

6 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Voyager Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.70% of the stock of Voyager Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VYGR
• CIK: 1640266
• Web: www.voyagertherapeutics.com
• Phone: (857) 259-5340
• Fax: N/A
• Employees: 141
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Voyager Therapeutics: $16.50
• High Price Target: $25.00
• Low Price Target: $8.00
• Potential Upside/Downside: +573.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$119.72 million
• Net Margins: -312.63%
• Pretax Margin: -312.26%
• Return on Equity: -57.92%
• Return on Assets: -45.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.51
• Quick Ratio: 7.51

Sales & Book Value

• Annual Sales: $40.37 million
• Price / Sales: 3.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.53 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 61,620,000
• Free Float: 53,793,000
• Market Cap: $150.97 million
• Optionable: Optionable
• Beta: 1.28